COMP <GO>
PCRX vs JNJ // RETURN ON INVESTED CAPITAL (ROIC)
Pacira BioSciences Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: PCRX 3
— JNJ 7
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: JNJ
LAST: $36.39 (0.00%) • MKT CAP: $1.45B
roic
1.70%
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
roic
25.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PCRX VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PCRX | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 79.40% | 67.90% | +11.50 | PCRX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 1.70% | 25.50% | -23.80 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 51.6x | 18.5x | +33.10 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 9.42% | 2.97% | +6.45 | PCRX | /fcf-yield <GO> |
| Operating Margin | 2.60% | 34.70% | -32.10 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 1.00% | 28.50% | -27.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 3.60% | 6.00% | -2.40 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.33 | 5.59 | -3.26 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 83.2 | 62.1 | +21.10 | PCRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.45B | $662.49B | -$661.04B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PCRX REV | JNJ REV | PCRX GROSS % | JNJ GROSS % | PCRX FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $726.4M | $94.19B | 79.4% | 67.9% | $136.7M | $19.70B |
| FY 2024 | $701.0M | $88.82B | 75.7% | 69.1% | $178.8M | $19.84B |
| FY 2023 | $675.0M | $85.16B | — | — | $154.6M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PCRX // BETA —
JNJ // BETA 1.08